All In Biotech

BLA 761077 · Amgen INC

Aimovig

Erenumab-Aooe · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 17, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

66

11 Phase 3, 9 recruiting

FAERS reports

55,567

12,192 serious, 3,183 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 14, 2026.

AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )

Mechanism: Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AIMOVIG · ERENUMAB-AOOE 70MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Erenumab" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device difficult to use10,278
  • accidental exposure to product10,273
  • wrong technique in product usage process9,519
  • drug dose omission by device6,743
  • migraine5,427
  • drug ineffective4,511
  • headache3,684
  • constipation3,196
  • product storage error2,980
  • injection site pain2,934
  • off label use2,925
  • nausea2,559

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20141
20156
20164
201710
20187,441
201911,258
20208,628
20216,012
20225,931
20235,750
20245,180
20253,093
20262,252

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 148 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.